Clinical Trial Update: Tolerability and Efficacy of Adjuvant T-DM1 in Patients with HER2 Positive Breast Cancer After Incomplete Pathological Response to Neoadjuvant Chemotherapy Including Anti-HER2 Agents.

View source ↗

Summary

ClinicalTrials.gov entry describing a recruiting study to assess tolerability and efficacy of adjuvant ado-trastuzumab emtansine (T-DM1) in HER2-positive breast…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• ado-trastuzumab emtansine (Kadcyla) (ado-trastuzumab emtansine)

Snippet

Sponsor: Regina Elena Cancer Institute | Conditions: Breast Cancer | Status: RECRUITING